Bain leads $150M round to push blindness biotech's rare disease drug toward FDA
Alkeus Pharmaceuticals has raised $150 million via a Series B round in order to advance a precision medicine candidate to treat Stargardt disease, a currently incurable genetic disease that causes blindness in children and young adults.
The news, announced Monday, said that the financing would go toward pushing the drug candidate, gildeuretinol, towards the FDA and to NDA submission. The financing will also be used to expand the company — but exact specifics weren’t disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.